EU Investigates Ties Of India’s Lupin, Others To Generics Antitrust Acts
This article was originally published in PharmAsia News
Executive Summary
The European Union says it is investigating India's Lupin and other international drug makers for possible involvement in collusion involving generic blood-pressure drugs. According to the European Commission, the executive branch of the EU, it suspects Lupin, Teva Pharmaceutical, Krka, Mylan and Unichem Laboratories subsidiaries of participating in an effort to keep a generic off the market. The antitrust investigation is part of a wider commission probe into the operations of the pharmaceutical industry in general, including how makers of branded drugs compete with generics makers. The company at the core of this probe is Les Laboratoires Servier, maker of the Coversyl, or Aceon (perindopril) ACE Inhibitor. (Click here for more - a subscription may be required
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.